AMBER MARIE TORRES

Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family SAN ANTONIO, TX NPI 1053142240

General Payments — all program years on this page

$405.06

  • Category: General Payments
  • Program years: PY2024
  • Record count: 22
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $405.06 across 22 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $405.0622

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2024 $405.0622

Records — PY2024 (22)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1100270783 Novo Nordisk Inc $14.99 10/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100461744 Novo Nordisk Inc $22.25 11/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100473029 Novo Nordisk Inc $21.83 12/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100510551 Novo Nordisk Inc $22.35 11/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1100566706 Novo Nordisk Inc $22.54 09/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105395204 AstraZeneca Pharmaceuticals LP $23.70 12/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105397248 AstraZeneca Pharmaceuticals LP $17.90 10/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105808700 AstraZeneca Pharmaceuticals LP $15.00 12/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1108319007 ABBVIE INC. $21.31 10/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1108319009 ABBVIE INC. $23.81 11/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114529980 Exact Sciences Corporation $16.61 10/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116415861 GlaxoSmithKline, LLC. $15.00 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117702720 Amgen Inc. $14.03 12/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131428593 PFIZER INC. $15.15 11/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135529559 Lilly USA, LLC $21.68 10/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136190070 Organon Llc $19.76 12/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141739919 Merck Sharp & Dohme LLC $18.89 10/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141939227 Merck Sharp & Dohme LLC $17.33 11/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141959794 Merck Sharp & Dohme LLC $15.01 09/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141981377 Merck Sharp & Dohme LLC $15.08 12/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1146894099 Philips North America LLC $16.22 10/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1150152962 SHIELD THERAPEUTICS INC $14.62 11/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.